*In clinical studies of 171 patients with TED.1
TEPEZZA has been shown to reduce proptosis and improve diplopia in TED patients.1,*
*In clinical studies of 171 patients with TED. 1
Visible and nonvisible signs and
symptoms of TED can have a
debilitating impact on your patients’
daily activities and self-confidence3-5
In clinical studies:
Reduced proptosis1
Improved diplopia1,6
TEPEZZA was also studied for impact on:
Inflammation7
Patient-reported ability to perform daily activities2,8,9
TEPEZZA has been studied in 4
published clinical trials with ~5
years of real-world
experience2,8,9,11,12
Complete the Patient Enrollment Form to get your patient started on TEPEZZA
Patients with commercial insurance may be eligible for a $0 co-pay for the cost of the medication and the infusion administration through our Amgen Commercial Co-Pay Program*
Hi I'm Kimberly Cockerham and I'm a board certified ophthalmologist with sub-specialty training in orbit, plastics and neuroophthalmology.
Thyroid Eye Disease is a vision-threatening, chronic disorder. Patients usually present with bulging of their eyes, redness, swelling, and complete disfigurement. They don't feel good about how they look, they're in pain. They're angry, and frustrated.
When somebody comes in and they're experiencing these symptoms, what are they really going through? It is very likely that a patient has seen multiple other practitioners with no results. I've had numerous patients who are approaching a decade or more of failed therapeutics.
Now things are different. Prior to January of 2020 when TEPEZZA was FDA approved as the first targeted treatment for Thyroid Eye Disease, there weren't a lot of options. Now I have TEPEZZA. It acts pretty quickly, and TEPEZZA makes the muscles behind the eye smaller. The redness and swelling go away. So, it's given me another tool in my tool chest.
Because of TEPEZZA, my conversations with my patients have changed for the better. I have a patient, and she gave me a picture of herself just before the Thyroid Eye Disease started. And then she showed me a picture of her in the midst of the disease, all alone, sad, frustrated. And then she sent me a picture just a couple of weeks after her last infusion, and her proptosis had improved, her eyes weren't bulging, she was really looking much more like herself again, and there she was, with her son, her grandchild and just beaming.
Each patient’s Thyroid Eye Disease journey is different, but it's really rewarding to be part of these patients' lives. Now, with TEPEZZA, I can help impact that journey.
Offer cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription. Not valid for prescriptions reimbursed in whole or in part by any government-funded program including but not limited to Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, or any state, patient foundation, or other pharmaceutical program. Offer good only in the United States at participating specialty pharmacies or sites of care. Offer not valid where otherwise prohibited by law, for example by applicable state law prohibiting co-pay cards. Amgen reserves the right to rescind, revoke, or amend offer without notice. The selling, purchasing, trading, or counterfeiting of any co-pay card or benefits is prohibited by law. This co-pay program is not insurance and is not intended to substitute for insurance. Age for eligibility is dependent on product indication.
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.
Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
Please see Full Prescribing Information for more information.
WARNINGS AND PRECAUTIONS Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions
